Palliative Radiotherapy Given Concurrently or Within 4 Weeks of Initiation of Immunotherapy Is Associated With Sustained Clinical Response to Immune Checkpoint Inhibitors in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
International Journal of Radiation Oncology Biology Physics - Netherlands
doi 10.1016/j.ijrobp.2019.06.2454
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2019
Authors
Publisher
Elsevier BV